Table 2.
TACE and TACE substrates levels in CAD patients and controls.
| TACE | Controls (n = 114) |
CAD (n = 225) |
p valuea | |||
|---|---|---|---|---|---|---|
| Median, 1st, 3rd quartile | Median 1st, 3rd quartile | |||||
| TACE mRNA expression levels/GAPDH (fold change norm to Controls) | 1.04, 0.68, 1.47 | 1.43, 0.96, 2.07 | <0.001 | |||
| TACE plasma levels (pg/ml) | 128.8, 0, 404.9 | 0, 0, 351.07 | 0.634 | |||
| TACE cell protein levels (pg/ml) (n = 36/80) |
222.1, 153.2, 208.9 |
301.5240.32, 443.05 |
<0.001 |
|||
| TACE substrates | ||||||
| Protein | Olink panel | Controls (n = 89) | CAD (n = 208) | p valuea | ||
| Immune system |
Mean (NPX) |
SD |
Mean (NPX) |
SD |
||
| IL1R2 | CVDII | 4.28 | 0.31 | 4.33 | 0.36 | 0.218 |
| IL-6R | CVDIII | 10.77 | 0.34 | 10.84 | 0.40 | 0.926 |
| TNFR1 | CVDIII | 5.31 | 0.33 | 5.79 | 0.63 | 0.356 |
| TNFR2 | CVDIII | 3.71 | 0.31 | 4.05 | 0.55 | 0.928 |
| LDLR | CVDIII | 2.73 | 0.66 | 2.85 | 0.56 | 0.006 |
| SORT1 | CVDII | 7.63 | 0.26 | 7.75 | 0.32 | 0.249 |
| TNFα | Inflammation | 0.05 | 0.33 | 0.04 | 0.38 | 0.553 |
| TRANCE | Inflammation | 4.17 | 0.71 | 4.30 | 0.72 | 0.045 |
| CSF-1 | Inflammation | 7.63 | 0.20 | 7.57 | 0.29 | 0.072 |
| LAG-3 | Immune | 1.71 | 0.50 | 1.54 | 0.45 | <0.001 |
| Development and differentiation | ||||||
| TGFα | Inflammation | 2.92 | 0.29 | 3.00 | 0.52 | 0.564 |
| HB-EGF | CVDII | 4.99 | 0.63 | 4.96 | 0.72 | 0.869 |
| AREG | Immune | 1.12 | 0.55 | 1.15 | 0.59 | 0.378 |
| FLT-3L | Inflammation | 8.63 | 0.47 | 8.72 | 0.52 | 0.881 |
| Cell adhesion | ||||||
| ALCAM | CVDIII | 4.47 | 0.23 | 4.51 | 0.26 | 0.815 |
| JAM-A | CVDIII | 4.60 | 0.59 | 4.86 | 0.76 | 0.084 |
| Ep-CAM | CVDIII | 4.89 | 1.03 | 4.78 | 0.95 | 0.756 |
| Others | ||||||
| ACE-2 | CVDII | 3.44 | 0.56 | 4.10 | 0.70 | <0.001 |
Plasma levels of TACE substrates TNFR1, HB-EGF and Ep-CAM are significantly different in ACS compared to elective CAD patients.
a
p value after FDR correction and adjusted for age, gender, BMI and cholesterol levels between the two groups.